GoodRx Holdings (GDRX) Research & Development (2019 - 2026)

GoodRx Holdings has disclosed Research & Development across 8 years of filings, most recently posting $82.0 million for Q2 2026.

• In Q2 2026, Research & Development fell 3.4% year-over-year to $82.0 million; the TTM figure through Jun 2026 stood at $325.2 million (down 7.91% YoY), while the FY2025 annual figure was $331.6 million, down 9.68% from the prior year.
• Research & Development came in at $82.0 million for Q2 2026 at GoodRx Holdings, up from $81.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $94.3 million in Q2 2022 to a low of $77.4 million in Q2 2023.
• Average Research & Development over 5 years is $86.7 million, with a median of $85.5 million recorded in 2022.
• Year-over-year, Research & Development fell 21.0% in 2022 and advanced 20.68% in 2024.
• Over 5 years, Research & Development stood at $84.1 million in 2022, then rose by 11.44% to $93.8 million in 2023, then increased by 0.08% to $93.8 million in 2024, then slipped by 16.21% to $78.6 million in 2025, then rose by 4.29% to $82.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $82.0 million in Q2 2026, $81.1 million in Q1 2026, and $78.6 million in Q4 2025.